Heart Failure and Atrial Fibrillation, Like Fire and Fury.
Adrenergic beta-Antagonists
/ therapeutic use
Anti-Arrhythmia Agents
/ therapeutic use
Anticoagulants
/ therapeutic use
Atrial Fibrillation
/ complications
Atrial Remodeling
/ physiology
Calcium Channel Blockers
/ therapeutic use
Cardiac Glycosides
/ therapeutic use
Cardiac Resynchronization Therapy
Catheter Ablation
Heart Failure
/ complications
Humans
Inflammation
/ physiopathology
Ventricular Remodeling
/ physiology
atrial fibrillation
catheter ablation
heart failure
rate control
rhythm control
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
22
10
2018
revised:
19
02
2019
accepted:
12
03
2019
entrez:
1
6
2019
pubmed:
31
5
2019
medline:
21
10
2020
Statut:
ppublish
Résumé
Heart failure and atrial fibrillation are 2 common cardiovascular disorders that frequently complicate one another and exert a significant detrimental effect on cardiovascular health and well-being. Both heart failure and atrial fibrillation continue to increase in prevalence as the risk factors underlying each condition become more common. This review encompasses what is currently known about the epidemiology and pathophysiology of these comorbidities along with incorporation of landmark trials that have contributed to current guidelines. The focus is on clinically relevant considerations, including the contribution of inflammation in the pathophysiology of atrial fibrillation and heart failure. We explore the emerging role of catheter ablation relative to medical therapy in the management of heart failure with reduced ejection fraction, along with indications for biventricular pacing modalities in cardiac resynchronization therapy. We discuss current guideline-directed therapies and how practice models and national recommendations will likely change based on the most recent randomized controlled trials.
Identifiants
pubmed: 31146871
pii: S2213-1779(19)30171-4
doi: 10.1016/j.jchf.2019.03.005
pii:
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Anti-Arrhythmia Agents
0
Anticoagulants
0
Calcium Channel Blockers
0
Cardiac Glycosides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-456Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL007101
Pays : United States
Informations de copyright
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.